The triple combination therapy of PD1-PD-L1 blockade, CTLA-4 blockade, and RANKL blockade further increased the proportion of tumor-infiltrating CD4+ and CD8+ T cells that can produce both IFN-γ and TNF [89]. The gene discussed is TNFSF11; the disease is neoplasm.